Update: Johnson & Johnson Fiscal Q3 Adjusted Earnings Fall, Sales Increase; Fiscal 2026 Guidance Lifted

09:19 AM EDT, 10/13/2026 (MT Newswires) -- (Updates with CFO comments on planned spinoff of orthopedics unit in sixth paragraph, updates stock move in last paragraph.) Johnson & Johnson (JNJ) reported fiscal Q3 adjusted earnings Tuesday of $2.59 per diluted share, down from $2.80 a year earlier. Analysts polled by FactSet expected $2.52. Reported sales for the fiscal quarter ended Sept. 27 were $25.40 billion, up from $23.99 billion a year earlier. Analysts polled by FactSet expected $25.38 billion. For fiscal 2026, the pharmaceuticals major lifted its projected adjusted EPS guidance to between $11.05 and $11.15 from a previous range of $10.96 to $11.11. Analysts polled by FactSet expect $11.19 The company lifted its reported sales for fiscal 2026 to be between $101.0 billion and $101.4 billion from a previous range of $100.8 billion to $101.4 billion. Analysts polled by FactSet expect $101.33 billion. Johnson & Johnson CFO Joe Wolk told CNBC in an interview that the company is targeting mid-2027 for the spinoff of its orthopedics unit DePuy Synthes. Johnson & Johnson said late last year it planned to spin off the unit into a standalone company, CNBC said. Johnson & Johnson shares were down 2.2% in premarket activity.